Recent Posts
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences
- Lifesaving Capital: How impact investing is shaping the future of biotech
- Investor Relations: the quiet advantage powering ASX microcaps
- HealthInvest Sydney: Life Sciences in the Investor Spotlight
- HealthInvest September 2025
Archives
Interview with Assoc.Prof. Mathias Francois of Gertrude Biomedical

We talk to Associate Professor Mathias Francois of Gertrude Biomedical, world-leaders in small molecular inhibitors to SOX18, a unique drug target with significant commercial and clinical potential
